Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Oronsky

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Human Vaccines & Immunotherapeutics|March 14, 2023
Profile EpicentRx, IncBryan Oronsky
Journal of Cellular and Molecular Medicine|July 17, 2018
Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001Bryan Oronsky, Neil Oronsky, Pedro Cabrales
Journal of Drug Targeting|May 21, 2021
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomasBryan Oronsky, Tony Reid, Pedro Cabrales
European Urology|September 26, 2017
A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum DoubletsChristina Brzezniak, Bryan Oronsky, Rahul Aggarwal
International Journal of Molecular Sciences|December 11, 2022
What Exactly Is Inflammation (and What Is It Not?)Bryan Oronsky, Scott Caroen, Tony Reid
American Journal of Cancer Research|August 15, 2022
AdAPT-001, an oncolytic adenovirus armed with a TGF-β trap, overcomes <i>in vivo</i> resistance to PD-L1-immunotherapyChristopher Larson, Bryan Oronsky, Tony Reid
Journal for Immunotherapy of Cancer|December 22, 2023
Commentary on oncolytic viruses: past, present, and futureChristopher Larson, Bryan Oronsky, Tony R Reid
Journal of Cancer Research and Clinical Oncology|June 29, 2019
RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibitionBryan Oronsky, Curtis Scribner, Rahul Aggarwal, et al.
Clinical Epigenetics|May 14, 2016
RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumorsBryan Oronsky, Jan Scicinski, Pedro Cabrales, et al.
Seminars in Oncology|March 10, 2020
Locally advanced rectal cancer: The past, present, and futureBryan Oronsky, Tony Reid, Chris Larson, et al.
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Human Vaccines & Immunotherapeutics|March 14, 2023
Profile EpicentRx, IncBryan Oronsky
Journal of Cellular and Molecular Medicine|July 17, 2018
Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001Bryan Oronsky, Neil Oronsky, Pedro Cabrales
Journal of Drug Targeting|May 21, 2021
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomasBryan Oronsky, Tony Reid, Pedro Cabrales
European Urology|September 26, 2017
A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum DoubletsChristina Brzezniak, Bryan Oronsky, Rahul Aggarwal
International Journal of Molecular Sciences|December 11, 2022
What Exactly Is Inflammation (and What Is It Not?)Bryan Oronsky, Scott Caroen, Tony Reid
American Journal of Cancer Research|August 15, 2022
AdAPT-001, an oncolytic adenovirus armed with a TGF-β trap, overcomes <i>in vivo</i> resistance to PD-L1-immunotherapyChristopher Larson, Bryan Oronsky, Tony Reid
Journal for Immunotherapy of Cancer|December 22, 2023
Commentary on oncolytic viruses: past, present, and futureChristopher Larson, Bryan Oronsky, Tony R Reid
Journal of Cancer Research and Clinical Oncology|June 29, 2019
RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibitionBryan Oronsky, Curtis Scribner, Rahul Aggarwal, et al.
Clinical Epigenetics|May 14, 2016
RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumorsBryan Oronsky, Jan Scicinski, Pedro Cabrales, et al.
Seminars in Oncology|March 10, 2020
Locally advanced rectal cancer: The past, present, and futureBryan Oronsky, Tony Reid, Chris Larson, et al.
Pageof 12